Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSDuchenne muscular dystrophy (DMD) is a rare X-linked progressive genetic disorder and the most common and severe type of dystrophinopathy. It is characterized by mutations in the DMD gene that prevent the production of functional dystrophin, a structural protein involved in maintaining the integrity of muscle cells. The absence of dystrophin in muscles leads to muscle degeneration, loss of ambulation and cardiomyopathy. According to statistics from the National Organization for Rare Disorders (USA), DMD occurs in approximately one out of every 3,500 male infants worldwide. The current therapies alleviate the symptoms and have been shown to slow the progression of the disease. Newer exon skipping therapies can halt the progression of DMD but only work in a subset of DMD patients with certain gene mutations and do not cure the disease. The first phase III DMD gene therapy program commenced patient enrollment in January 2021 and following this milestone, a gene therapy to deliver a healthy copy of the dystrophin gene may provide a cure for this debilitating disease. This article will provide an update on current treatment options for DMD and outline the latest development activities of key experimental drugs with data sourced from IQVIA Pipeline Intelligence, a proprietary drug pipeline database.
Corticosteroids, including prednisone and deflazacort, have been commonly used to treat DMD. Corticosteroids act by delaying the progression of muscle weakness and reducing inflammation by inhibiting the expression of pro-inflammatory genes. While the first corticosteroid won US FDA approval for the treatment of DMD in 2017, the widely available generic prednisone is frequently prescribed for the disease but does not have formal US FDA approval.
Antisense-mediated exon skipping therapiesGene-targeted treatments have also been investigated for DMD, including exon skipping therapies which mask specific exons in a gene sequence of the DMD gene and gene therapies to deliver a healthy DMD gene directly to a patient. There are currently four antisense-mediated exon skipping therapies approved by the US FDA for DMD.
Recent progress has been made in the development of gene therapies to cover all patients regardless of mutation. Despite the identification of the dystrophin gene in 1986, which is the largest human gene (2,200 kb in size), it has proved a challenge to transfer the gene into adeno-associated viruses (AAV) used to deliver gene therapies due to its size. As the carrying capacity of AAVs is approximately 4.7 kb, instead of utilizing the full dystrophin gene, researchers engineered smaller, modified genes that produce a shortened form of dystrophin: micro-dystrophin (gene size 3.5 to 4 kb) and mini-dystrophin (gene size 6 to 8 kb) that are designed to function like the normal dystrophin protein. There are currently several key gene therapies in clinical development for DMD.
GENOME-EDITING THERAPIESWith the development of genome editing systems, including CRISPR/Cas9 it is now possible to make targeted modifications in the genome. Gene-editing therapies can restore the expression of partially functional dystrophin protein by reframing DMD mutations at the genomic level and potentially provide a cure for the disease. Although no CRISPR-based therapies have entered clinical development yet, several companies are working on CRISPR programs for DMD.
FUTURE DIRECTIONSMany advances have been made over the last few decades in elucidating the molecular mechanisms of DMD since the discovery of the dystrophin gene, which has aided the emergence of new gene-based therapies. This has opened the door for combination therapies, with the use of gene therapies to stabilize muscle and small molecule drugs such as anti-inflammatory therapies to combat the downstream effects of fibrosis and inflammation. The latest developments could provide DMD patients further treatment options and potentially increased benefit.